Evommune Statistics
Total Valuation
Evommune has a market cap or net worth of $852.19 million. The enterprise value is $667.60 million.
Important Dates
The last earnings date was Thursday, March 5, 2026, after market close.
| Earnings Date | Mar 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Evommune has 36.02 million shares outstanding. The number of shares has increased by 306.86% in one year.
| Current Share Class | 36.02M |
| Shares Outstanding | 36.02M |
| Shares Change (YoY) | +306.86% |
| Shares Change (QoQ) | +1,179.99% |
| Owned by Insiders (%) | 2.59% |
| Owned by Institutions (%) | 40.71% |
| Float | 19.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 62.67 |
| Forward PS | n/a |
| PB Ratio | 3.58 |
| P/TBV Ratio | 3.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 51.35 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.57, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.57 |
| Quick Ratio | 8.33 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11,581.57 |
Financial Efficiency
Return on equity (ROE) is -54.42% and return on invested capital (ROIC) is -39.64%.
| Return on Equity (ROE) | -54.42% |
| Return on Assets (ROA) | -33.67% |
| Return on Invested Capital (ROIC) | -39.64% |
| Return on Capital Employed (ROCE) | -39.16% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $270,833 |
| Profits Per Employee | -$1.43M |
| Employee Count | 48 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 23.22 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 48.55 |
| Average Volume (20 Days) | 330,442 |
Short Selling Information
The latest short interest is 3.03 million, so 8.40% of the outstanding shares have been sold short.
| Short Interest | 3.03M |
| Short Previous Month | 2.51M |
| Short % of Shares Out | 8.40% |
| Short % of Float | 15.44% |
| Short Ratio (days to cover) | 2.63 |
Income Statement
In the last 12 months, Evommune had revenue of $13.00 million and -$68.87 million in losses. Loss per share was -$11.22.
| Revenue | 13.00M |
| Gross Profit | 13.00M |
| Operating Income | -81.07M |
| Pretax Income | -68.87M |
| Net Income | -68.87M |
| EBITDA | -79.68M |
| EBIT | -81.07M |
| Loss Per Share | -$11.22 |
Full Income StatementBalance Sheet
The company has $149.20 million in cash and $2.06 million in debt, with a net cash position of $147.14 million or $4.09 per share.
| Cash & Cash Equivalents | 149.20M |
| Total Debt | 2.06M |
| Net Cash | 147.14M |
| Net Cash Per Share | $4.09 |
| Equity (Book Value) | 205.57M |
| Book Value Per Share | 6.52 |
| Working Capital | 135.57M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$76.44 million and capital expenditures -$235,000, giving a free cash flow of -$76.68 million.
| Operating Cash Flow | -76.44M |
| Capital Expenditures | -235,000 |
| Depreciation & Amortization | 1.39M |
| Net Borrowing | -531,000 |
| Free Cash Flow | -76.68M |
| FCF Per Share | -$2.13 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -623.62% |
| Pretax Margin | -529.77% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Evommune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -306.86% |
| Shareholder Yield | -306.86% |
| Earnings Yield | -8.45% |
| FCF Yield | -9.41% |
Analyst Forecast
The average price target for Evommune is $43.29, which is 82.97% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $43.29 |
| Price Target Difference | 82.97% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Evommune has an Altman Z-Score of 15.99 and a Piotroski F-Score of 1.
| Altman Z-Score | 15.99 |
| Piotroski F-Score | 1 |
